Rik Ossenkoppele
111 – 120 of 174
      - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2021
- 
                        Mark
        Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
    
    - Contribution to journal › Article
 
- 
                        Mark
        Four distinct trajectories of tau deposition identified in Alzheimer’s disease
    
    - Contribution to journal › Article
 
- 
                        Mark
        Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β–negative cognitively normal individuals
    
    - Contribution to journal › Article
 
- 
                        Mark
        The impact of demographic, clinical, genetic, and imaging variables on tau PET status
    
    - Contribution to journal › Article
 
- 
                        Mark
        Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
    
    - Contribution to journal › Article
 
- 
                        Mark
        Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies
    
    - Contribution to journal › Article
 
- 
                        Mark
        Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia
    
    - Contribution to journal › Article
 
- 
                        Mark
        Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups
    
    - Contribution to journal › Article
 
- 
                        Mark
        Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
    
    - Contribution to journal › Scientific review
 
- 
                        Mark
        Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
    
    - Contribution to journal › Scientific review
 
